Other interventions showing some benefit in only one study were benzydamine, calcium phosphate, honey, oral care protocols, povidone and zinc sulphate. Conclusions Several of the interventions were found to have some benefit at preventing or reducing the severity of mucositis associated with cancer treatment. The strength of the evidence was variable and implications for practice include consideration that benefits may be specific for certain cancer types and treatment. There is a need for welldesigned RCT with sufficient numbers of participants to perform subgroup analyses by type of disease and chemotherapeutic agent.
Commentary
The clinical question asked in this review is an important one. Oral mucositis (OM) occurs in up to 100% of patients undergoing bone marrow transplant, is associated with fever, infection and 100-day mortality, 1 and is one of the most debilitating side effects of transplantation. 2 In patients receiving radiotherapy for head and neck malignancies, OM is the major dose-limiting side effect and has the potential to cause significant treatment interruptions or premature termination of therapy, with resultant impact on local tumour control and patient survival. Quality of life may be greatly compromised because of severe pain and nutritional impairment. Treatment of the symptoms of OM may necessitate narcotic analgesics, enteral feeding and hospitalisation, adding significantly to the overall costs of treatment. 1 This report uses the established, scientifically sound systematic review methods of the Cochrane Collaboration, and follows earlier work by the authors in the area of oral complications associated with cytotoxic cancer therapy. The authors report some benefit from several interventions, but the evidence is weak and is insufficient to guide practice. For instance, it is reported that amifostine, the intervention with the largest body of evidence in this review (five studies, comprising 446 patients) appears to have some, minimal, benefit for patients undergoing radiotherapy to the head and neck. It was reported that it did not affect survival at 24 months, recurrence at 18 months or incomplete response to radiation treatment, but there has been debate regarding theoretical concerns that amifostine may also protect tumour cells: long-term data are still unavailable to alleviate those concerns.
For another intervention, topical antibiotics, a large, multicentre RCT published in 2002 3 apparently was not identified by the search strategy. In that study of 137 patients, no difference was seen between the antibiotic lozenge and placebo control, data which may have affected the findings of the review.
Although ice chips were found to be beneficial, this finding is limited to the specific patient population undergoing 5FU (5 Flurouracil ) chemotherapy and is based on two trials, one of which was considered to be of medium risk and the other at high risk for bias.
As this review indicates, evidence remains elusive regarding the prevention and treatment of OM in people being treated for cancer, despite the fact that the current update has identified 19 more trials in less than 2 years. The authors point out significant flaws with past research in OM, common to many studies reported in the biomedical literature, although it is encouraging that several negative trials have been published. Study design and resulting useable data has been hampered by several factors, including lack of standardised outcome measures for OM, and intrastudy variability in disease types and sites and cytotoxic regimens. [4] [5] [6] The biological complexities of OM at the molecular, cellular and tissue levels, as well as genetic influences and interaction with the local tissue environment, have only recently been understood, 7, 8 In this light, it is not surprising that past research, much of it based on empiricism rather than strong biological rationale, has failed to Ecological studies SR (with homogeneity*) of case-control studies * By homogeneity we mean a systematic review that is free of worrisome variations (heterogeneity) in the directions and degrees of results between individual studies. Not all systematic reviews with statistically significant heterogeneity need be worrisome, and not all worrisome heterogeneity need be statistically significant.
